Requires a report to be produced that focuses on prescription drug prior authorizations by January 1, 2026.
H5433 amends the Rhode Island Health Care Reform Act of 2004 to expand and update the duties of the health insurance commissioner and the Office of the Health Insurance Commissioner (OHIC). The bill preserves and restates a broad set of oversight responsibilities, including holding quarterly public meetings on insurer rates and operations, making recommendations to the governor and legislative finance committees, convening advisory councils and workgroups, and producing reports on health insurance market issues, behavioral health parity, hospital payment variation, mandated benefits, accountable care organizations, and other insurance-related topics.
A central new requirement in the bill is a report due by January 1, 2026 that focuses on prescription drug prior authorizations. The bill also directs OHIC and related workgroups to study and promote administrative simplification in health care, including electronic eligibility verification, standardized claims and coding processes, prior authorization procedures, continuity of care, and provider-payer communication. In addition, the bill retains provisions directing OHIC to analyze market-merger issues, reinsurance, mental health parity, behavioral health integration, and social and human service reimbursement and accountability.
The bill primarily affects the statutory powers and duties of the health insurance commissioner under Rhode Island General Laws § 42-14.5-3. It does not create a new insurance program or change coverage mandates directly, but it expands the commissioner’s reporting, analysis, and oversight obligations, including a new report on prescription drug prior authorization and continued work on provider-payer administrative standards. The bill also reinforces OHIC’s role in monitoring insurer practices, coordinating stakeholder workgroups, and producing policy recommendations that may influence future regulation, legislation, and market oversight for insurers, providers, employers, patients, and state agencies.
The available context suggests generally favorable or at least supportive sentiment toward the bill’s goals, particularly its focus on improving oversight and reducing administrative burdens in health care. The bill was introduced by a group of House members and referred to the House Health & Human Services Committee, but no committee transcript or vote record is provided here, so there is no evidence of formal opposition or amendment debate in the supplied materials. The caption emphasizes the prescription drug prior authorization report, indicating that this was a key policy objective.
The bill’s most likely points of contention are the scope and burden of OHIC’s expanded responsibilities, the extent to which insurers and providers must comply with reporting and process-standardization efforts, and the policy implications of prior authorization reform. Stakeholders that may differ include health insurers, providers, hospitals, behavioral health organizations, small businesses, and consumer advocates. The bill also touches on sensitive issues such as market merging, rating guidelines, reinsurance, mandated benefits, and behavioral health parity, any of which could draw differing views depending on their expected effects on premiums, access, and administrative costs.